As we reflect on 2024, it’s clear that this year has been a defining chapter in Cartherics’ 10-year history. We’ve experienced significant milestones, overcome challenges, and made bold strides toward advancing our mission. The work on ovarian cancer has progressed with the autologous CAR-T product under preclinical evaluation by the Peter MacCallum Cancer Centre, […]
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar in recognition of his exceptional scholarly performance. His impactful work and high-quality contributions have earned him a spot in the top 0.05% of 30 million scholars globally, ranking highly across seven fields. Notably, Alan is […]
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of German, Austrian and Swiss newspapers. Barbara’s article, translated below, was published in a number of European newspapers, highlighting that the first baby born from a frozen embryo is now 40 years old – a result […]
Melbourne, Australia, 17 October 2023 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately. He holds extensive experience from a diverse scientific background encompassing both academic research and […]
Commercialising science and technology is key to the continued growth of Australia’s vibrant life sciences industry. Translating research into real-world results has important implications for consumers and businesses alike.
Bio Connections Australia 2023 was held today at Crown Promenade Melbourne with an important focus on translation, drug development and expediting Australia’s science into commercialisation.
The forum […]
The 2023 Australia-China Science and Innovation Forum focused on leading-edge Australian and Chinese biomedical research collaborations and commercialisation. The forum was held at Monash University’s Suzhou campus in China last week and was also available for online attendance.
The forum’s program was designed to promote connections and enhance collaborations between the Australian and Chinese research and […]
Cartherics’ Director of IP & Licensing, Telma Mantas recently attended the ACI’s 21st Advanced Summit on Life Sciences Patents in New York City. The summit provided the opportunity to engage in face-to-face discussions with leading stakeholders on the best practices to enhance global protections for patent portfolios. Now more than ever in these increasingly […]
Cartherics is delighted to announce that Rasa Islam has successfully completed her PhD candidature.
Rasa’s research thesis, titled, Re-engineering the function of natural killer cell receptors via CRISPR/Cas9: a new approach for ‘off the shelf’ immunotherapy, investigated the generation of Natural Killer (NK) cells (immune cells) from gene-edited stem cells to provide an ‘off-the-shelf’ supply for […]
Cartherics is pleased to announce that PhD Candidate, Van To, will be presenting at the Association for Cancer Immunotherapy’s 20th CIMT Annual Meeting in Germany.
CIMT is Europe’s largest meeting focused on cancer immunotherapy research and development. Every year, the CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As […]
Cartherics recently held a company offsite at the RACV Healesville Country Club and Resort. Nestled in the beautiful Yarra Valley just over an hour from Melbourne, the venue provided a relaxing escape for the Cartherics team to engage, connect and grow as individuals and a team.
We heard from motivational speakers, took part in a personal […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
